Silence Therapeutics Agrees to $1.3 Billion Merck KGaA Acquisition at 130% Premium
Silence Therapeutics (SLN) agreed to a $1.3 billion all-cash acquisition by Merck KGaA at $20 per ADS, a 130% premium. The deal, pending approvals, is expected to close in Q1 2027. SLN's Phase 2 progress for Divesiran, an investigational siRNA treatment, was a key factor. Shareholders with 14% voting power support the transaction, which requires shareholder, court, and regulatory approvals.
How this was made
The 30-second read
Why it matters
The transaction locks in a premium, removing upside from future clinical milestones but providing immediate cash value to shareholders.
Market read
The deal is a material M&A event for a US‑listed biotech, likely moving SLN stock toward the $20 offer price and influencing biotech M&A sentiment.
What to watch
Potential integration challenges for the siRNA platform and competition from other RNA therapeutics.
Background
Silence Therapeutics (NASDAQ:SLN) is a clinical‑stage biotech developing Divesiran for polycythemia vera. Merck KGaA announced a cash acquisition at $20 per ADS.
Ticker impact
Silence Therapeutics agreed to be acquired by Merck KGaA for $20 per ADS, a 130% premium to its recent price.
likely upward pressure as the market prices in the cash offer, but potential downside if shareholder or regulatory approval stalls.
The acquisition is a fresh, material M&A announcement with a $1.3 B equity value, creating immediate price impact.
Market effects
Adds a siRNA platform to Merck KGaA, potentially boosting the biotech M&A landscape.
European pharma M&A activity may see heightened interest.
Large‑cap Merck KGaA expands its rare‑disease pipeline, influencing global biotech sentiment.
Counterpoint
If regulatory or court approvals face delays, the deal could collapse, sending SLN shares sharply lower.
Key entities
- companySilence Therapeutics
Biotech developing siRNA therapy Divesiran.
- companyMerck KGaA
German pharmaceutical group expanding its rare‑disease portfolio.
